Decreased Bone Resorption with Soy Isoflavone Supplementation in Postmenopausal Women

Harkness, Laura; K, Fiedler; Sehgal, Ashwini R.; Oravec, D; Lerner, Edith

doi:10.1089/jwh.2004.13.1000

Cited by 78 publications

(45 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our literature search identified 31 RCTs. Twenty-two studies were excluded because of lack of indices of interest (Agnusdei et al, 1997a, b;Gambacciani et al, 1997a, b;Potter et al, 1998;Alekel et al, 2000;Wangen et al, 2000;Clifton-Bligh et al, 2001;Katase et al, 2001;Anderson et al, 2002;Chiechi et al, 2002;Lucas et al, 2002;Chen et al, 2003Chen et al, , 2004Jones et al, 2003;Schult et al, 2003;Atkinson et al, 2004;Harkness et al, 2004;Olsen et al, 2004;Mori et al, 2004a, b), non-randomization (Dalais et al, 1998), lack of a control group (Agnusdei et al, 1997a, b), insufficient original data or baseline values (Gambacciani et al, 1997a, b;Khalil et al, 2002). Thus, nine studies with a total of 432 subjects were included in this meta-analysis, in which five studies had quality score of five; three studies had quality score of four and one study had quality score of three (Morabito et al, 2002;Uesugi et al, 2002;Yamori et al, 2002;Arjmandi et al, 2003Arjmandi et al, , 2005Dalais et al, 2003;Brooks et al, 2004;Mori et al, 2004a, b;Nikander et al, 2004) (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…Then they further indicated that high bone turnover is a risk factor for osteoporosis (Ravn et al, 1997). Harkness et al (2004) found that soy isoflavones significantly decreased bone resorption and significantly increased bone mineral density within 24 weeks. Recently, some RCTs reported that isoflavone intake less than 6 months significantly increased bone mineral density or bone mineral content (Alekel et al, 2000;Mori et al, 2004a, b).…”

Section: Effects Of Isoflavone On Bone Resorption and Formation D-f Mmentioning

confidence: 99%

See 1 more Smart Citation

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

et al. 2007

Eur J Clin Nutr

130

View full text Add to dashboard Cite

Objective: To clarify the effects of isoflavone intake on bone resorption and bone formation. Methods: We identified randomized controlled trials related to urinary deoxypyridinoline (Dpyr, a bone resorption marker) and serum bone-specific alkaline phosphatase (BAP, a bone formation marker) listed on MEDLINE (January 1966-April 2006, the Cochrane Controlled Trials Register, EMBASE (1985( -January 2006, Science Citation Index and PUBMED (updated till April 2006). Results: Nine studies with a total of 432 subjects were selected for meta-analysis. The urinary Dpyr concentration in subjects who consumed isoflavones decreased significantly by À2.08 nmol/mmol (95% confidence interval (CI): À3.82 to À0.34 nmol/ mmol) in comparison with that in subjects who did not consume isoflavones. Isoflavone intake vs placebo intake significantly increased serum BAP by 1.48 mg/l (95% CI: 0.22-2.75 mg/l). Decreases in the urinary Dpyr concentration with isoflavone intake of o90 mg/day and with treatment lasting less than 12 weeks were À2.34 nmol/mmol (95% CI: À4.46 to À0.22 nmol/mmol) and À2.03 nmol/mmol (95% CI: À3.20 to À0.85 nmol/mmol), respectively. Conclusions: Isoflavone intervention significantly inhibits bone resorption and stimulates bone formation. These favorable effects occur even if o90 mg/day of isoflavones are consumed or the intervention lasts less than 12 weeks.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Effects Of Isoflavone On Bone Resorption and Formation D-f Mmentioning

confidence: 99%

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

et al. 2007

Eur J Clin Nutr

130

View full text Add to dashboard Cite

show abstract

“…Some studies in postmenopausal women reported significant decrease in bone resorption markers (Crisafulli et al 2004;Evans et al 2007) in contrast to the others who reported nonsignificant changes in bone resorption markers (Albertazzi et al 2005;Wangen et al 2000) and bone formation markers (Albertazzi et al 2005;Weaver et al 2009). In addition, the BMD changes after phytoestrogens intake were reported controversially (Cook and Pennington 2002;Kritz-Silverstein and Goodman-Gruen 2002;Harkness et al 2004). Concerning the importance of bone biomarkers in clinical trials, we analyzed the effect of the phytoestrogens on bone markers.…”

Section: Discussionmentioning

confidence: 99%

Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: a meta-analysis

Salari

Nikfar

Abdollahi

2010

AGE

View full text Add to dashboard Cite

Phytoestrogens as selective estrogen receptor modulators like compounds may consider as a therapeutic option in osteoporosis. In this regard, the effect of phytoestrogens on bone biomarkers was examined in several trials which their results are controversial. We aimed this meta-analysis to evaluate the net effect of phytoestrogens on bone markers. A thorough search was conducted from 2000 to 2010 in English articles. All randomized clinical trials were reviewed, and finally, 11 eligible randomized clinical trials were selected for meta-analysis. Totally 1,252 postmenopausal women were enrolled in the study by considering the changes of pyridinoline (Pyd), desoxypyridinoline (Dpyd), bone alkaline phosphatase, and osteocalcin concentrations in urine and serum after phytoestrogens consumption. The urine Pyd and Dpyd levels decreased significantly in phytoestrogens consumers. Effect size and effect size for weighted mean difference of urine Pyd levels showed −1.229171 (95% confidence interval (CI)=−1.927639 to −0.530703) and −9.780623 (95% CI=−14.240401 to −5.320845), respectively, a significant results in comparison to control group and significant results for Dpyd −0.520132 (95% CI=−0.871988 to −0.168275) and −0.818582 (95% CI=−1.247758 to −0.389407), respectively. Metaanalysis indicates that phytoestrogens intake can prevent bone resorption, but its benefits on bone formation are not significant. This favorable effect

show abstract

“…02) and at 15 months (P < 0 . 05) in the group given IF-free soyabean compared with the other two groups Harkness et al (84) n 19, mean age 70 . 6 (SD 6 .…”

Section: Mechanisms Of Actionmentioning

confidence: 96%

“…It has been suggested that the differences may be a result of synergies or antagonisms among the flavones, threshold (81) Post-menopausal women 40 g ground flaxseed or wheat-based comparative control regimen daily 3 Markers of bone formation and resorption not affected by either of the treatments Arjmandi et al (82) n 71 40 g soyabean protein/d 3 Decrease in urinary DPD Dalais et al (83) Post-menopausal women, n 106 3 No effect on markers for bone resorption (urinary excretion of pyridinoline or deoxypyridinoline) Harkness et al (84) Post-menopausal women, n 19, mean age 70 . 6 (SD 6 .…”

Section: Urinary Isoflavone Excretion Over 24 H (Gc-ms)mentioning

confidence: 99%

Phyto-oestrogens and bone health

Coxam

2008

Proc. Nutr. Soc.

View full text Add to dashboard Cite

As oestrogen deficiency is the main cause in the pathogenesis of osteoporosis hormonereplacement therapy remains the mainstay for prevention. However, prophylaxis by hormonereplacement therapy is limited. Phyto-oestrogens, which are weakly-oestrogenic compounds present in plants, deserve particular mention because emerging data support the suggestion that they may prevent bone loss associated with the menopause. In the past few years extensive research using animal models has provided convincing data to indicate a significant improvement in bone mass or other end points following feeding with soyabean. Moreover, observational studies relate the lower incidence of osteoporosis among women in the Eastern world to a diet rich in phyto-oestrogens. However, it is not valid to extrapolate to the Western situation. The varied clinical trials that have been published suggest that isoflavones reduce bone loss in women in the early period post menopause, but a definitive result requires more investigations of the effect of phyto-oestrogens on bone health that have substantial sample size and are of long duration. In addition, the clinical efficacy of soya foods in preventing osteopenia depends on their intestinal metabolism. Thus, phyto-oestrogens are a source for putative innovative dietary health intervention for post-menopausal women. However, more data are necessary, particularly in relation to their effect on the risk of fracture. Phyto-oestrogens: Osteoporosis: Post-menopausal womenOsteoporosis, a systemic skeletal disease characterized by a low bone mass and microarchitectural deterioration, is one of society's most debilitating and costly diseases, particularly in elderly women and increasingly in men. It has become a worldwide problem that is expected to worsen in many countries with ageing populations; the lifetime risk for osteoporotic fracture is 40 % for women and approximately 15% for men (1) . This condition is characterized by an imbalance between the deposition of matrix and mineralization and the resorption activity resulting from an impairment in the remodelling process as a result of changes in the functional lifespan of osteoclasts and osteoblasts (2) .Hormonal changes during the menopausal transition, which ultimately result in a decline in oestrogen, play a pivotal role in the development of this chronic disease (3) . Indeed, oestrogens exhibit a broad range of physiological activities that are important in the homeostasic regulation of many cells, including bone cells. In women the menopause initiates an accelerated phase of predominantly cancellous bone loss that declines rapidly over 5-10 years to become asymptotic, with a subsequent slow phase that continues indefinitely. Oestrogen deficiency affects remodelling in several ways: it increases the activation frequency of bone modelling units, which leads to higher bone turnover; it induces a remodelling imbalance by prolonging the resorption phase and shortening the formation phase. As a consequence, the volume of the resorption cavity increases b...

show abstract

Decreased Bone Resorption with Soy Isoflavone Supplementation in Postmenopausal Women

Abstract: Soy isoflavone, in isolated form, was effective in this study to significantly decrease bone resorption in postmenopausal women. Further investigation needs to be done to evaluate the long-term effects of soy isoflavone on bone mass and fracture risk.

Cited by 78 publications

References 22 publications

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: a meta-analysis

Phyto-oestrogens and bone health

Contact Info

Product

Resources

About